A practical reference on peptide hormone: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-07-22. Anything still debated is marked as such rather than presented as settled.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
== References == Siegel, David P.; Cherezov, V.; Greathouse, D. V.; Koeppe, R. E.; Antoinette Killian, J.; Caffrey, M. (January 2006). "Transmembrane Peptides Stabilize Inverted Cubic Phases in a Biphasic Length-Dependent Manner: Implications for Protein-Induced Membrane Fusion". Biophysical Journal. 90 (1). Biophysical Society: 200–211. Bibcode:2006BpJ....90..200S. doi:10.1529/biophysj.105.070466. PMC 1367019. PMID 16214859. Weiss, Thomas M.; Van der Wel, Patrick C.A.; Antoinette Killian, J.; Koeppe, II, Roger E.; Huang, Huey W. (January 2003). "Hydrophobic Mismatch between Helices and Lipid Bilayers". Biophysical Journal. 84 (1). Biophysical Society: 379–385. Bibcode:2003BpJ....84..379W. doi:10.1016/S0006-3495(03)74858-9. PMC 1302619. PMID 12524291. Kim, Taehoon; Im, Wonpil (July 2010). "Revisiting Hydrophobic Mismatch with Free Energy Simulation Studies of Transmembrane Helix Tilt and Rotation". Biophysical Journal. 99 (6). Biophysical Society: 175–183. Bibcode:2010BpJ....99..175K. doi:10.1016/j.bpj.2010.04.015. PMC 2895360. PMID 20655845.
In August, the Federal Police (PF) launched Operations Carbono Oculto, Quasar and Tank against a multibillion-real scheme of fraud in the fuel sector and money laundering, revealing that the First Capital Command (PCC) and companies in the financial market used fintechs and transactions via PIX to move and conceal large sums. According to the investigation, the absence of oversight, intensified by the disinformation that circulated on social media about the new Federal Revenue Service oversight rule that would be implemented at the beginning of the year but was revoked due to fake news, facilitated the criminal group's activity. Later, deputies requested the investigation of Nikolas over the video in which he criticized the new oversight of financial movements via Pix."These fake news were so strong that, despite all the effort of the Federal Revenue Service, we could not overcome these lies, because of the strength of those who boosted them. [...] And today's operations show who gained from these lies, from these fake news". — Robinson Barreirinhas, special secretary of the Federal Revenue Service.
Oxytocin+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) "Symbol Report: OXTR". HUGO Gene Nomenclature Committee. "Vasopressin and Oxytocin Receptors: OT". The International Union of Basic and Clinical Pharmacology, The British Pharmacological Society, The University of Edinburgh. International Union of Basic and Clinical Pharmacology. This article incorporates text from the United States National Library of Medicine, which is in the public domain.
"Waser (1967) describes the effects of self-administration of 10–15 mg. of muscimol as '. . . intense hallucinations as with LSD were missing . . . there resulted considerable disturbances of psychic functions, such as orientation in space and time, visual perception, process of thinking, speech, and some new psychic phenomena of illusions and echo pictures'. Higher doses tended to produce severe intoxication in man, with painful muscular twitching, considerable agitation, and vivid hallucinations." The effects of muscimol in humans in different studies have been found to include sedation, central depression, dizziness, incoordination or clumsiness, relaxation, reduced anxiety, mood improvement or euphoria, sleep, rich dreaming, difficulty speaking, impaired attention, focus, and concentration, impaired learning, confusion, a glassy-eyed stare, loss of appetite, stimulation, agitation, hallucinogenic effects, echo-like pseudohallucinations (visual and auditory, vivid hallucinations, dissociation, psychosis, and delirium). At higher doses, coma, seizures, and death can occur. Physical effects of muscimol can include muscle twitching or tremors, flushing, slightly increased blood pressure, nausea, vomiting, abdominal pain, diarrhea, and increased salivation, among others. After-effects have been reported to include fatigue, inactivity, and headache and migraine. Some can find the hallucinogenic effects of muscimol to be highly unpleasant, for instance one person being "shaken and frightened" by the experience.
Sources: en.wikipedia.org
=== COVID-19 === In 2020, the monoclonal antibody therapies bamlanivimab/etesevimab and casirivimab/imdevimab were given emergency use authorizations by the US Food and Drug Administration to reduce the number of hospitalizations, emergency room visits, and deaths because of COVID-19. In September 2021, the Biden administration purchased US$2.9 billion worth of Regeneron monoclonal antibodies at $2,100 per dose to curb the shortage. As of December 2021, in vitro neutralization tests indicate monoclonal antibody therapies (with the exception of sotrovimab and tixagevimab/cilgavimab) were not likely to be active against the Omicron variant. Over 2021–22, two Cochrane reviews found insufficient evidence for using neutralizing monoclonal antibodies to treat COVID-19 infections. The reviews applied only to people who were unvaccinated against COVID‐19, and only to the COVID-19 variants existing during the studies, not to newer variants, such as Omicron. In March 2024, pemivibart, a monoclonal antibody drug, received an emergency use authorization from the US FDA for use as pre-exposure prophylaxis to protect certain moderately to severely immunocompromised individuals against COVID-19.
== Discovery == In 1948, Sutherland and De Duve identified a gastrointestinal glucagon-like material in gastric mucosa, the term "enteroglucagon" was used to describe this material that shared a similar immunoreactivity with glucagon. A half-century later, Brubaker and Drucker studied proglucagon gene expression, they discovered the function of enteroglucagon is related to the growth of intestinal epithelium.
Los Zetas originated in 1999, when Gulf Cartel leader Osiel Cárdenas Guillén recruited 37 former elite soldiers from Mexico's special forces to serve as his armed wing. Known as Los Zetas, they operated as the cartel's private army and played a central role in its dominance of the drug trade in the early 2000s. After Cárdenas Guillén's 2007 arrest and extradition, Los Zetas broke away under Heriberto Lazcano, building independent networks in drug, arms, and human trafficking. By 2008, they had allied with the Beltrán Leyva brothers, turning against their former partners, the Gulf Cartel. In 2010, the split became open war, with Los Zetas and the Gulf Cartel fighting for control of routes in northeast Mexico, which resulted in thousands of deaths. In July 2013, the Mexican Navy arrested leader Miguel Treviño Morales. Los Zetas are notorious for targeting civilians, including the mass murder of 72 migrants in the San Fernando massacre. Their activities extended beyond narcotics and have also been connected to human trafficking, oil theft from pipelines, extortion, and digital piracy. Their criminal network is said to reach far from Mexico, including into Central America, the U.S., and Europe. In recent times, Los Zetas have undergone fragmentation and infighting and seen a decline in their influence. By the late 2010s, the group had fragmented into rival factions such as Sangre Nueva Zeta and Zetas Vieja Escuela, some of which allied with the Gulf Cartel against the Cártel del Noreste. Remnants of Los Zetas have also operated under the Cártel del Noreste name.
H–D exchange has been used to characterize protein structures and protein–protein interactions. The exchange reaction needs to be carried out with the isolated proteins and with the complex. The exchanging regions are then compared. If a region is buried by the binding, the amides in this region may be protected in the complex and exchange slowly. However, one must bear in mind that H–D exchange cannot be used to locate binding interfaces for all protein-protein interactions. Some protein-protein interactions are driven by electrostatic forces of side chains and are unlikely to change the exchange rate of backbone amide hydrogens, particularly if the amide hydrogens are located in stable structural elements such as alpha helices. Lastly, H–D exchange can be used to monitor conformational changes in proteins as they relate to protein function. If conformation is altered as result of post-translational modification, enzyme activation, drug binding or other functional events, there will likely be a change to H/D exchange that can be detected.
Liquefied gases, such as liquid nitrogen and liquid helium, are used in many cryogenic applications. Liquid nitrogen is the most commonly used element in cryogenics and is legally purchasable around the world. Liquid helium is also commonly used and allows for the lowest attainable temperatures to be reached. These liquids may be stored in Dewar flasks, which are double-walled containers with a high vacuum between the walls to reduce heat transfer into the liquid. Typical laboratory Dewar flasks are spherical, made of glass and protected in a metal outer container. Dewar flasks for extremely cold liquids such as liquid helium have another double-walled container filled with liquid nitrogen. Dewar flasks are named after their inventor, James Dewar, the man who first liquefied hydrogen. Thermos bottles are smaller vacuum flasks fitted in a protective casing. Cryogenic barcode labels are used to mark Dewar flasks containing these liquids, and will not frost over down to −195 degrees Celsius. Cryogenic transfer pumps are the pumps used on LNG piers to transfer liquefied natural gas from LNG carriers to LNG storage tanks, as are cryogenic valves.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.